Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 121 resultater
Tid
Selskap
Tittel
Sektor
Kategori
24 Apr 2024
23:00 CEST
BIOPHYTIS
Biophytis Announces Transfer of ADSs to OTC Market
20103010 Biotechnology
Other subject
24 Apr 2024
23:00 CEST
BIOPHYTIS
Biophytis annonce le transfert de ses ADS sur le marché OTC
20103010 Biotechnology
Other subject
19 Apr 2024
07:00 CEST
BIOPHYTIS
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
20103010 Biotechnology
Other subject
19 Apr 2024
07:00 CEST
BIOPHYTIS
Biophytis annonce un changement de ratio pour son programme d\'American Depositary Receipt (
20103010 Biotechnology
Other subject
18 Apr 2024
07:00 CEST
BIOPHYTIS
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
20103010 Biotechnology
Other subject
18 Apr 2024
07:00 CEST
BIOPHYTIS
Biophytis annonce la création d\'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l\'obésité
20103010 Biotechnology
Other subject
15 Apr 2024
07:00 CEST
BIOPHYTIS
Biophytis dépose une demande de brevet et renforce sa propriété intellectuelle dans l’obésité
20103010 Biotechnology
Other subject
15 Apr 2024
07:00 CEST
BIOPHYTIS
Biophytis files a patent application and strengthens its intellectual property in obesity
20103010 Biotechnology
Other subject
08 Apr 2024
23:12 CEST
BIOPHYTIS
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
20103010 Biotechnology
Other subject
08 Apr 2024
23:12 CEST
BIOPHYTIS
Biophytis announces its 2023 financial results and provides an update on its business activities
20103010 Biotechnology
Other subject
08 Apr 2024
23:10 CEST
BIOPHYTIS
Biophytis lance l\'étude clinique de phase 2 OBA dans l\'obésité avec BIO101 (20-hydroxyecdysone)
20103010 Biotechnology
Other subject
08 Apr 2024
23:10 CEST
BIOPHYTIS
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
20103010 Biotechnology
Other subject
04 Apr 2024
23:00 CEST
BIOPHYTIS
RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
20103010 Biotechnology
Other subject
04 Apr 2024
23:00 CEST
BIOPHYTIS
RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
20103010 Biotechnology
Other subject
22 Mar 2024
07:00 CET
BIOPHYTIS
Biophytis presented its phase 3 protocol in the treatment of sarcopenia
20103010 Biotechnology
Other subject
22 Mar 2024
07:00 CET
BIOPHYTIS
Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
20103010 Biotechnology
Other subject
18 Mar 2024
07:00 CET
BIOPHYTIS
Combined General Meeting of April 2, 2024
20103010 Biotechnology
Other subject
18 Mar 2024
07:00 CET
BIOPHYTIS
Assemblée générale mixte du 02 avril 2024
20103010 Biotechnology
Other subject
15 Mar 2024
23:00 CET
BIOPHYTIS
Biophytis announces the implementation of a reverse stock split of its ordinary shares traded on Euronext Growth
20103010 Biotechnology
Other subject
15 Mar 2024
23:00 CET
BIOPHYTIS
Biophytis annonce le lancement du regroupement des actions composant son capital social
20103010 Biotechnology
Other subject
12 Mar 2024
07:00 CET
BIOPHYTIS
Biophytis announces its participation in several events in Europe and the United States over the coming months
20103010 Biotechnology
Other subject
12 Mar 2024
07:00 CET
BIOPHYTIS
Biophytis annonce sa participation à plusieurs événements en Europe et aux Etats-Unis au cours des prochains mois
20103010 Biotechnology
Other subject
08 Mar 2024
07:00 CET
BIOPHYTIS
Biophytis a présenté le potentiel de RuvembriTM dans le traitement de la dystrophie musculaire de Duchenne
20103010 Biotechnology
Other subject
08 Mar 2024
07:00 CET
BIOPHYTIS
Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy
20103010 Biotechnology
Other subject
22 Feb 2024
07:00 CET
BIOPHYTIS
« Vivre longtemps en bonne santé » - Publication d’un livre sur la médecine et la science de la longévité
20103010 Biotechnology
Legal
22 Feb 2024
07:00 CET
BIOPHYTIS
\"Live healthier longer\" - Publication of a book on the medicine and science of longevity
20103010 Biotechnology
Legal
04 Jan 2024
07:00 CET
BIOPHYTIS
Biophytis annonce la publication des résultats de son étude de phase 2-3 COVA dans eClinicalMedicine, partie de The Lancet
20103010 Biotechnology
Other subject
04 Jan 2024
07:00 CET
BIOPHYTIS
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet
20103010 Biotechnology
Other subject
29 Dec 2023
07:00 CET
BIOPHYTIS
Biophytis annonce le tirage de la quatrième tranche d\'ORNANE dans le cadre du contrat Atlas 2021
20103010 Biotechnology
Legal
29 Dec 2023
07:00 CET
BIOPHYTIS
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract
20103010 Biotechnology
Legal
11 Dec 2023
07:00 CET
BIOPHYTIS
Biophytis announces its participation in several conferences in Europe and the US during the first quarter of 2024
20103010 Biotechnology
Legal
11 Dec 2023
07:00 CET
BIOPHYTIS
Biophytis annonce sa participation à plusieurs conférences en Europe et aux Etats-Unis au cours du premier trimestre 2024
20103010 Biotechnology
Legal
04 Dec 2023
07:00 CET
BIOPHYTIS
Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure
20103010 Biotechnology
Other subject
04 Dec 2023
07:00 CET
BIOPHYTIS
Biophytis et l’Université de Liège explorent le potentiel de Sarconeos (BIO101) dans le traitement de l’insuffisance respiratoire virale
20103010 Biotechnology
Other subject
27 Nov 2023
07:00 CET
BIOPHYTIS
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board
20103010 Biotechnology
Other subject
27 Nov 2023
07:00 CET
BIOPHYTIS
Biophytis nomme Yann Meunier et Bernard Lévy à son comité scientifique
20103010 Biotechnology
Other subject
20 Nov 2023
07:00 CET
BIOPHYTIS
Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million
20103010 Biotechnology
Other subject
20 Nov 2023
07:00 CET
BIOPHYTIS
Biophytis annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription pour un montant d’environ 1,96 M€
20103010 Biotechnology
Other subject
17 Nov 2023
23:00 CET
BIOPHYTIS
Biophytis reçoit une notification du Nasdaq
20103010 Biotechnology
Other subject
17 Nov 2023
23:00 CET
BIOPHYTIS
Biophytis announces receipt of Nasdaq Notice
20103010 Biotechnology
Other subject
06 Nov 2023
07:00 CET
BIOPHYTIS
Biophytis participe à BIO-Europe à Munich
20103010 Biotechnology
Other subject
06 Nov 2023
07:00 CET
BIOPHYTIS
Biophytis to attend BIO-Europe in Munich
20103010 Biotechnology
Other subject
01 Dec 2022
08:03 CET
BIOPHYTIS
BIOPHYTIS ORGANISE UN WEBCAST EN PRÉSENCE DE KEY OPINION LEADERS (KOL) SUR LES RÉSULTATS DE L\'ÉTUDE COVA DE PHASE 2-3 DE SARCONEOS (BIO101) DANS LE TRAITEMENT DE LA PNEUMONIE CHEZ LES PATIENTS COVID-19 À RISQUE D\'INSUFFISANCE RESPIRATOIRE
20103010 Biotechnology
Legal
03 Nov 2022
10:42 CET
BIOPHYTIS
Biophytis rapporte l’analyse post-hoc positive de l’étude de phase 2-3 COVA soutenant fortement le potentiel thérapeutique de Sarconeos (BIO101) dans les formes sévères de la COVID-19
20103010 Biotechnology
Legal
03 Nov 2022
08:00 CET
BIOPHYTIS
Biophytis rapporte l’analyse post-hoc positive de l’étude de phase 2-3 COVA soutenant fortement le potentiel thérapeutique de Sarconeos (BIO101) dans les formes sévères de la COVID-19
20103010 Biotechnology
Legal
31 Oct 2022
23:00 CET
BIOPHYTIS
Biophytis publie ses principaux agrégats financiers au 30 juin 2022, annonce un retraitement des états financiers publiés au 31 décembre 2021 et fait un point sur les développements opérationnels
20103010 Biotechnology
Legal
26 Oct 2022
08:00 CEST
BIOPHYTIS
Biophytis reçoit une notification du Nasdaq
20103010 Biotechnology
Legal
15 Sep 2022
08:00 CEST
BIOPHYTIS
Biophytis participe à la 24ème Global Investment Conference de HC Wainwright à New York
20103010 Biotechnology
Legal
16 Dec 2021
08:00 CET
BIOPHYTIS
Rencontre prévue avec la FDA pour faire avancer le développement de Sarconeos (BIO101) dans la sarcopénie de la phase 2 à la phase 3
20103010 Biotechnology
Legal
22 Nov 2021
23:00 CET
BIOPHYTIS
Biophytis obtient une nouvelle structure de prêt de 10 M€ avec Kreos Capital
20103010 Biotechnology
Legal
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva